PBH · Prestige Consumer Healthcare In
$47.26
-0.17% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$4B
Trailing P/E
13.6
Forward P/E
9.3
Dividend yield
—
Beta
0.33
Avg volume
1M
Employees
1K
Daily Change %
-0.17%
5 Days Change
-6.81%
10 Days Change
-5.95%
30 Days Change
-9.14%
60 Days Change
-0.41%
Month to Day Change
-7.48%
Year to Day Change
-21.06%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PBH
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-15
Latest call per bank · past 12 months
Jefferies
Hold$66.00
+39.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-15 | Canaccord Genuity | Maintains | Buy | $86.00 → $72.00 |
| 2026-05-14 | Oppenheimer | Downgrade | Outperform → Perform | $0.00 |
| 2026-05-07 | Oppenheimer | Maintains | Outperform | $77.00 → $65.00 |
| 2026-02-02 | Jefferies | Maintains | Hold | $70.00 → $66.00 |
| 2025-11-07 | Canaccord Genuity | Maintains | Buy | $100 → $88.00 |
| 2025-10-27 | Jefferies | Maintains | Hold | $75.00 → $71.00 |
| 2025-10-21 | Oppenheimer | Maintains | Outperform | $82.00 → $72.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 35 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.9% below the 50-day MA ($50.74).
- Price vs 200-day MA: Trading 16.5% below the 200-day MA ($56.58).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.61) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($45.44).
PBH Price Chart
Loading chart for PBH…
Fundamentals
About Prestige Consumer Healthcare In
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$58B 16.8% YTD
TEVA
Teva Pharmaceutical Industries
$42B 18.1% YTD
HLN
Haleon plc
$41B -6.9% YTD
ZTS
Zoetis Inc.
$30B -40.8% YTD
UTHR
United Therapeutics Corporation
$22B 4.0% YTD
VTRS
Viatris Inc.
$19B 35.6% YTD
NBIX
Neurocrine Biosciences, Inc.
$16B 9.4% YTD
ELAN
Elanco Animal Health Incorporat
$11B 4.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.